Ignyta, Inc. Watch

EX-10.1

from 8-K 6 pages Agreement

12/34/56

EX-10.1

from 8-K 36 pages Ignyta, Inc. 2017 Employment Inducement Incentive Award Plan Article 1. Purpose

12/34/56

EX-10.2

from 10-Q 81 pages Certain Material (Indicated by an Asterisk) Has Been Omitted From This Document Pursuant to a Request for Confidential Treatment. the Omitted Material Has Been Filed Separately With the Securities and Exchange Commission. Amended and Restated License, Development and Commercialization Agreement Dated as of March 22, 2017 by and Between Eli Lilly and Company and Ignyta, Inc

12/34/56

EX-10.27

from 10-K 3 pages Ignyta, Inc. Non-Employee Director Compensation Program Effective as of March 9, 2017

12/34/56

EX-10.1

from 10-Q 20 pages Ignyta, Inc. Severance and Change in Control Severance Plan and Summary Plan Description

12/34/56

EX-10.1

from S-3/A 93 pages Certain Material (Indicated by an Asterisk) Has Been Omitted From This Document Pursuant to a Request for Confidential Treatment. the Omitted Material Has Been Filed Separately With the Securities and Exchange Commission. License, Development and Commercialization Agreement Dated as of November 6, 2015 by and Between Eli Lilly and Company and Ignyta, Inc

12/34/56

EX-10.3

from S-3 16 pages Registration Rights Agreement

12/34/56

EX-10.2

from S-3 27 pages Stock Purchase Agreement by and Between Ignyta, Inc. and Eli Lilly and Company Dated as of November 6, 2015

12/34/56

EX-10.1

from S-3 93 pages Certain Material (Indicated by an Asterisk) Has Been Omitted From This Document Pursuant to a Request for Confidential Treatment. the Omitted Material Has Been Filed Separately With the Securities and Exchange Commission. License, Development and Commercialization Agreement Dated as of November 6, 2015 by and Between Eli Lilly and Company and Ignyta, Inc

12/34/56

EX-10.2

from 8-K 16 pages Fifth Amendment to Lease

12/34/56

EX-10.1

from 8-K 87 pages Lease by and Between Bmr-Axiom LP, a Delaware Limited Partnership and Ignyta, Inc., a Delaware Corporation

12/34/56

EX-10.1

from 8-K 36 pages Ignyta, Inc. 2015 Employment Inducement Incentive Award Plan Article 1. Purpose

12/34/56

EX-10.7

from 10-Q 56 pages (1) Cancer Research Technology Limited and (2) Teva Branded Pharmaceutical Products R&D, Inc. Licence

12/34/56

EX-10.6

from 10-Q 76 pages Collaboration Agreement

12/34/56

EX-10.1

from 10-Q 8 pages Ignyta, Inc. 2014 Incentive Award Plan Restricted Stock Unit Award Grant Notice and Restricted Stock Unit Award Agreement

12/34/56

EX-10.1

from 8-K 25 pages Material contract

12/34/56

EX-10.2

from 8-K 18 pages Registration Rights Agreement

12/34/56

EX-10.1

from 8-K 52 pages Asset Purchase Agreement by and Between Ignyta, Inc. and Cephalon, Inc. Dated as of March 17, 2015

12/34/56

EX-10.1

from 8-K/A 3 pages Certain Material (Indicated by an Asterisk) Has Been Omitted From This Document Pursuant to a Request for Confidential Treatment. the Omitted Material Has Been Filed Separately With the Securities and Exchange Commission. Amendment No 2. to License Agreement

12/34/56

EX-10.1

from 10-Q/A 33 pages Certain Material (Indicated by an Asterisk) Has Been Omitted From This Document Pursuant to a Request for Confidential Treatment. the Omitted Material Has Been Filed Separately With the Securities and Exchange Commission. License Agreement

12/34/56